Human Liver Proteome Project (HLPP)

The liver is a central organ in human body that controls metabolic homeostasis, provide essential substances to the organism and allow detoxification of xenobiotics. In addition to its biological function, liver physiology is peculiar in different aspects, including its regeneration capacity. Despite the intense research performed during the last couple of decades, there are still many open questions in regard of the molecular mechanisms underlying liver function and, most importantly, liver disease. This constraint largely restricts the development of more efficient diagnostic and therapeutic strategies for the better management of the patients. In the postgenomic era, the Human Liver Initiative started in 2002 as a large-scale international collaborative initiative aiming to define a comprehensive and dynamic map of the human liver proteome.

Current lines of work:

• Definition of liver proteome by characterization of all specific liver cell types and their interaction in health and disease.
• Definition of priority protein lists relevant in liver physiology and participating in the molecular pathogenesis of liver disorders. Example: panel of 15 enzymes of One Carbon Metabolism.
• To develop targeted standardized methods for the quantification of clinically relevant proteins. Example: SRM assay for a panel of 12 enzymes of One Carbon Metabolism.
• In depth dynamic characterization of liver regeneration by a combination of proteomics and phosphoproteomics.
• To identify novel proteins relevant in liver biology and pathology by means of proteogenomics.
• Identify differentially expressed proteins in Hepatocellular carcinoma (HCC) patients who underwent liver transplantaion, using proteomics of vascular invation, well differentiated, moderate differentiated, and poor differentiated liver biopsies
• Non Alcoholic Fatty Liver Disease (NAFLD) molecular characterization and early marker discovery.
• Analysis of molecular mechanisms in drug induced liver injury.
• To study the role of ubiquitin-like proteins in liver disease.

Related web-address links:

European Association for the Study of the Liver: www.easl.eu

Links to other HPP groups:

Leadership:

• Fernando J. Corrales, Chair
  
• Pumin Zhang, Co-chair

Upcoming Meetings:

• C-HPP Symposium. May 12-14, 2019
• XIV annual Meeting of the Italian Proteomics Association. June 25-27, 2019.
• 18th HUPO World Congress. September 15-18, 2019.

Publications:

• Liver cancer-associated changes to the proteome: what deserves clinical focus? Mato JM, Elortza F, Lu SC, Brun V, Paradela A, Corrales FJ. Expert Rev Proteomics. 2018 Sep;15(9):749-756. doi: 10.1080/14789450.2018.1521277. Epub 2018 Sep 19. PMID:30204005

• Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria. Serrano-Mendioroz I, Sampedro A, Serna N, de Salamanca RE, Sanz-Parra A, Corrales F, Berraondo P, Millet O, Fontanellas A. Hum Mol Genet. 2018 Nov 1;27(21):3688-3696. doi: 10.1093/hmg/ddy283. PMID:30085095

• Abundance of Cytochromes in Hepatic Extracellular Vesicles Is Altered by Drugs Related With Drug-Induced Liver Injury. Palomo L, Mleczko JE, Azkargorta M, Conde-Vancells J, González E, Elortza F, Royo F, Falcon-Perez JM. Hepatol Commun. 2018 Aug 23;2(9):1064-1079. doi: 10.1002/hep4.1210. eCollection 2018 Sep. PMID:30202821

• SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer. Zubiete-Franco I, García-Rodríguez JL, Lopitz-Otsoa F, Serrano-Macia M, Simon J, Fernández-Tussy P, Barbier-Torres L, Fernández-Ramos D, Gutiérrez-de-Juan V, López de Davalillo S, Carlevaris O, Beguiristain Gómez A, Villa E, Calvisi D, Martín C, Berra E, Aspichueta P, Beraza N, Varela-Rey M, Ávila M, Rodríguez MS, Mato JM, Díaz-Moreno I, Díaz-Quintana A, Delgado TC, Martínez-Chantar ML. EBioMedicine. 2018 Dec 26. pii: S2352-3964(18)30608-X. doi: 10.1016/j.ebiom.2018.12.031. [Epub ahead of print] PMID:30594553

• Prohibitin 1 Acts As a Negative Regulator of Wingless/Integrated-Beta-Catenin Signaling in Murine Liver and Human Liver Cancer Cells. Mavila N, Tang Y, Berlind J, Ramani K, Wang J, Mato JM, Lu SC. Hepatol Commun. 2018 Sep 27;2(12):1583-1600. doi: 10.1002/hep4.1257. eCollection 2018 Dec.PMID:30556043
  

• Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice. Morrison MC, Verschuren L, Salic K, Verheij J, Menke A, Wielinga PY, Iruarrizaga-Lejarreta M, Gole L, Yu WM, Turner S, Caspers MPM, Martínez-Arranz I, Pieterman E, Stoop R, van Koppen A, van den Hoek AM, Mato JM, Hanemaaijer R, Alonso C, Kleemann R. Hepatol Commun. 2018 Oct 29;2(12):1513-1532. doi: 10.1002/hep4.1270. eCollection 2018 Dec. PMID:30556039

• The mitochondrial chaperone Prohibitin 1 negatively regulates interleukin-8 in human liver cancers. Yang JW, Murray B, Barbier-Torres L, Liu T, Liu Z, Yang H, Fan W, Wang J, Li Y, Seki E, Mato JM, Lu SC. J Biol Chem. 2018 Dec 6. pii: jbc.RA118.004863. doi: 10.1074/jbc.RA118.004863. [Epub ahead of print] PMID:30523154
  

• MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. Fernández-Ramos D, Fernández-Tussy P, Lopitz-Otsoa F, Gutiérrez-de-Juan V, Navasa N, Barbier-Torres L, Zubiete-Franco I, Simón J, Fernández AF, Arbelaiz A, Aransay AM, Lavín JL, Beraza N, Perugorria MJ, Banales JM, Villa E, Fraga MF, Anguita J, Avila MA, Berasain C, Iruzibieta P, Crespo J, Lu SC, Varela-Rey M, Mato JM, Delgado TC, Martínez-Chantar ML. Cell Death Dis. 2018 Sep 20;9(10):958. doi: 10.1038/s41419-018-1014-y. PMID:30237481
  

• Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria. Urquiza P, Laín A, Sanz-Parra A, Moreno J, Bernardo-Seisdedos G, Dubus P, González E, Gutiérrez-de-Juan V, García S, Eraña H, San Juan I, Macías I, Ben Bdira F, Pluta P, Ortega G, Oyarzábal J, González-Muñiz R, Rodríguez-Cuesta J, Anguita J, Díez E, Blouin JM, de Verneuil H, Mato JM, Richard E, Falcón-Pérez JM, Castilla J, Millet O. Sci Transl Med. 2018 Sep 19;10(459). pii: eaat7467. doi: 10.1126/scitranslmed.aat7467. PMID:30232228
  

• Fine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver disease. Blokker BA, Maijo M, Echeandia M, Galduroz M, Patterson AM, Ten A, Philo M, Schungel R, Gutierrez-de Juan V, Halilbasic E, Fuchs C, Le Gall G, Milkiewicz M, Milkiewicz P, Banales JM, Rushbrook SM, Mato JM, Trauner M, Müller M, Martínez-Chantar ML, Varela-Rey M, Beraza N. Hepatology. 2018 Sep 19. doi: 10.1002/hep.30275. [Epub ahead of print] PMID:30229970
  

• Liver cancer-associated changes to the proteome: what deserves clinical focus? Mato JM, Elortza F, Lu SC, Brun V, Paradela A, Corrales FJ. Expert Rev Proteomics. 2018 Sep;15(9):749-756. doi: 10.1080/14789450.2018.1521277. Epub 2018 Sep 19. PMID:30204005

• Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Mayo R, Crespo J, Martínez-Arranz I, Banales JM, Arias M, Mincholé I, Aller de la Fuente R, Jimenez-Agüero R, Alonso C, de Luis DA, Vitek L, Stritesky J, Caballería J, Romero-Gómez M, Martín-Duce A, Mugüerza Huguet JM, Busteros-Moraza JI, Idowu MO, Castro A, Martínez-Chantar ML, Ortiz P, Bruha R, Lu SC, Bedossa P, Noureddin M, Sanyal AJ, Mato JM. Hepatol Commun. 2018 May 4;2(7):807-820. doi: 10.1002/hep4.1188. eCollection 2018 Jul. PMID:30027139

• Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer. Liu T, Yang H, Fan W, Tu J, Li TWH, Wang J, Shen H, Yang J, Xiong T, Steggerda J, Liu Z, Noureddin M, Maldonado SS, Annamalai A, Seki E, Mato JM, Lu SC. Gastroenterology. 2018 Aug;155(2):557-571.e14. doi: 10.1053/j.gastro.2018.04.032. Epub 2018 May 5. PMID:29733835
  

• Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Bril F, Millán L, Kalavalapalli S, McPhaul MJ, Caulfield MP, Martinez-Arranz I, Alonso C, Ortiz Betes P, Mato JM, Cusi K. Diabetes Obes Metab. 2018 Jul;20(7):1702-1709. doi: 10.1111/dom.13285. Epub 2018 Apr 14. PMID:29527789
  

• Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. Mölleken C, Ahrens M, Schlosser A, Dietz J, Eisenacher M, Meyer HE, Schmiegel W, Holmskov U, Sarrazin C, Sorensen GL, Sitek B, Bracht T. Clin Mol Hepatol. 2018 Nov 19. doi: 10.3350/cmh.2018.0029. [Epub ahead of print] PMID:30449076
  

• Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours. Nwosu ZC, Battello N, Rothley M, Piorońska W, Sitek B, Ebert MP, Hofmann U, Sleeman J, Wölfl S, Meyer C, Megger DA, Dooley S. J Exp Clin Cancer Res. 2018 Sep 3;37(1):211. doi: 10.1186/s13046-018-0872-6. Erratum in: J Exp Clin Cancer Res. 2018 Nov 2;37(1):267. PMID:30176945
  

• A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. Manceau V, Palard X, Rolland Y, Pracht M, Le Sourd S, Laffont S, Boudjema K, Lievre A, Mesbah H, Haumont LA, Lenoir L, Brun V, Uguen T, Edeline J, Garin E. Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1731-1741. doi: 10.1007/s00259-018-3990-7. Epub 2018 Mar 20. PMID:29560519

• Direct Quantification of Cytochromes P450 and Drug Transporters-A Rapid, Targeted Mass Spectrometry-Based Immunoassay Panel for Tissues and Cell Culture Lysates. Weiß F, Hammer HS, Klein K, Planatscher H, Zanger UM, Norén A, Wegler C, Artursson P, Joos TO, Poetz O. Drug Metab Dispos. 2018 Apr;46(4):387-396. doi: 10.1124/dmd.117.078626. Epub 2018 Jan 17. PMID:29343608
  

• Mixture effects of two plant protection products in liver cell lines. Zahn E, Wolfrum J, Knebel C, Heise T, Weiß F, Poetz O, Marx-Stoelting P, Rieke S. Food Chem Toxicol. 2018 Feb;112:299-309. doi: 10.1016/j.fct.2017.12.067. Epub 2017 Dec 30. PMID:29294346

• Targeting Endothelial Erk1/2-Akt Axis as a Regeneration Strategy to Bypass Fibrosis during Chronic Liver Injury in Mice. Lao Y, Li Y, Zhang P, Shao Q, Lin W, Qiu B, Lv Y, Tang L, Su S, Zhang H, Tian C, Sun A, Wei H, Zhang P, Wu Y, Jiang Y, He F. Mol Ther. 2018 Dec 5;26(12):2779-2797. doi: 10.1016/j.ymthe.2018.08.016. Epub 2018 Aug 24. PMID:30266653
  

• ER-associated ubiquitin ligase HRD1 programs liver metabolism by targeting multiple metabolic enzymes. Wei J, Yuan Y, Chen L, Xu Y, Zhang Y, Wang Y, Yang Y, Peek CB, Diebold L, Yang Y, Gao B, Jin C, Melo-Cardenas J, Chandel NS, Zhang DD, Pan H, Zhang K, Wang J, He F, Fang D. Nat Commun. 2018 Sep 10;9(1):3659. doi: 10.1038/s41467-018-06091-7. PMID:30201971

• Artificial MicroRNA-Mediated Tgfbr2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice. Jiang Y, Zhao Y, He F, Wang H. Hum Gene Ther. 2018 Nov 13. doi: 10.1089/hum.2018.047. [Epub ahead of print] PMID:30024280
  

• Germline Duplication of SNORA18L5 Increases Risk for HBV-related Hepatocellular Carcinoma by Altering Localization of Ribosomal Proteins and Decreasing Levels of p53. Cao P, Yang A, Wang R, Xia X, Zhai Y, Li Y, Yang F, Cui Y, Xie W, Liu Y, Liu T, Jia W, Jiang Z, Li Z, Han Y, Gao C, Song Q, Xie B, Zhang L, Zhang H, Zhang J, Shen X, Yuan Y, Yu F, Wang Y, Xu J, Ma Y, Mo Z, Yu W, He F, Zhou G. Gastroenterology. 2018 Aug;155(2):542-556. doi: 10.1053/j.gastro.2018.04.020. Epub 2018 Apr 24. PMID:29702115
  

• A proteomics landscape of circadian clock in mouse liver. Wang Y, Song L, Liu M, Ge R, Zhou Q, Liu W, Li R, Qie J, Zhen B, Wang Y, He F, Qin J, Ding C. Nat Commun. 2018 Apr 19;9(1):1553. doi: 10.1038/s41467-018-03898-2. PMID:29674717
  

• Dysregulated Response of Follicular Helper T Cells to Hepatitis B Surface Antigen Promotes HBV Persistence in Mice and Associates With Outcomes of Patients. Wang X, Dong Q, Li Q, Li Y, Zhao D, Sun J, Fu J, Meng F, Lin H, Luan J, Liu B, Wang M, Wang FS, He F, Tang L. Gastroenterology. 2018 Jun;154(8):2222-2236. doi: 10.1053/j.gastro.2018.03.021. Epub 2018 Mar 12. PMID:29544722
  

• In Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma. Ren L, Li C, Wang Y, Teng Y, Sun H, Xing B, Yang X, Jiang Y, He F. Mol Cell Proteomics. 2018 Jun;17(6):1067-1083. doi: 10.1074/mcp.RA117.000421. Epub 2018 Feb 22. PMID:29472430
  

• Cell-type-resolved alternative splicing patterns in mouse liver. Wu P, Zhou D, Lin W, Li Y, Wei H, Qian X, Jiang Y, He F. DNA Res. 2018 Jan 8. doi: 10.1093/dnares/dsx055. [Epub ahead of print] PMID:29325017
  

• Toward an understanding of the protein interaction network of the human liver. Wang J, Huo K, Ma L, Tang L, Li D, Huang X, Yuan Y, Li C, Wang W, Guan W, Chen H, Jin C, Wei J, Zhang W, Yang Y, Liu Q, Zhou Y, Zhang C, Wu Z, Xu W, Zhang Y, Liu T, Yu D, Zhang Y, Chen L, Zhu D, Zhong X, Kang L, Gan X, Yu X, Ma Q, Yan J, Zhou L, Liu Z, Zhu Y, Zhou T, He F, Yang X. Mol Syst Biol. 2017 Dec 18;13(12):965. doi: 10.15252/msb.20178107. No abstract available. PMID:29254952

• Genome-Wide Association Study Identifies a New Locus at 7q21.13 Associated with Hepatitis B Virus-Related Hepatocellular Carcinoma. Li Y, Zhai Y, Song Q, Zhang H, Cao P, Ping J, Liu X, Guo B, Liu G, Song J, Zhang Y, Yang A, Yan H, Yang L, Cui Y, Ma Y, Xing J, Shen X, Liu T, Zhang H, An J, Bei JX, Jia W, Kang L, Liu L, Yuan D, Hu Z, Shen H, Lu L, Wang X, Li H, He F, Zhang H, Zhou G. Clin Cancer Res. 2018 Feb 15;24(4):906-915. doi: 10.1158/1078-0432.CCR-17-2537. Epub 2017 Dec 15. PMID:29246937
  

• Disruption of peroxisome function leads to metabolic stress, mTOR inhibition, and lethality in liver cancer cells. Cai M, Sun X, Wang W, Lian Z, Wu P, Han S, Chen H, Zhang P. Cancer Lett. 2018 May 1;421:82-93. doi: 10.1016/j.canlet.2018.02.021. Epub 2018 Feb 17. PMID:29458144

• Acetylation of TIP60 at K104 is essential for metabolic stress-induced apoptosis in cells of hepatocellular cancer. Fang X, Lu G, Ha K, Lin H, Du Y, Zuo Q, Fu Y, Zou C, Zhang P. Exp Cell Res. 2018 Jan 15;362(2):279-286. doi: 10.1016/j.yexcr.2017.11.028. Epub 2017 Nov 22. PMID:29174981

• Analysis of Differentially Expressed Proteins in Hepatocellular Carcinoma. Baquerizo, Angeles1; Simonian, Margaret2; Frenette, Catherine1; Schaffer, Randolph1; Nelson, Mary1; Fisher, Jonathan1; Whiteledge, Julian2; Madani, Bahar1; Pockros, Paul1; Marsch, Christopher. Transplantation: July 2018 - Volume 102 - Issue - p S907 doi: 10.1097/01.tp.0000544012.65450.1b

• CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78).Aran G, Sanjurjo L, Bárcena C, Simon-Coma M, Téllez É, Vázquez-Vitali M, Garrido M, Guerra L, Díaz E, Ojanguren I, Elortza F, Planas R, Sala M, Armengol C, Sarrias MR. FASEB J. 2018 Jul;32(7):3878-3891. doi: 10.1096/fj.201700941RR. Epub 2018 Feb 20. 
• Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development.
• Uriarte I, Latasa MU, Carotti S, Fernandez-Barrena MG, Garcia-Irigoyen O, Elizalde M, Urtasun R, Vespasiani-Gentilucci U, Morini S, de Mingo A, Mari M, Corrales FJ, Prieto J, Berasain C, Avila MA.
• Int J Cancer. 2015 May 15;136(10):2469-75. doi: 10.1002/ijc.29287. Epub 2014 Nov 6.
• Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria.
• Serrano-Mendioroz I, Sampedro A, Mora MI, Mauleón I, Segura V, Enríquez de Salamanca R, Harper P, Sardh E, Corrales FJ, Fontanellas A.
• J Proteomics. 2015 Sep 8;127(Pt B):377-85. doi: 10.1016/j.jprot.2015.05.004. Epub 2015 May 13.
• Long-term metabolic correction of Wilson’s disease in a murine model by gene therapy.
• Murillo O, Luqui DM, Gazquez C, Martinez-Espartosa D, Navarro-Blasco I, Monreal JI, Guembe L, Moreno-Cermeño A, Corrales FJ, Prieto J, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G.
• J Hepatol. 2016 Feb;64(2):419-26. doi: 10.1016/j.jhep.2015.09.014. Epub 2015 Sep 25.
• Methylthioadenosine regulates liver cells proteome and methylproteome. Implications in liver biology and disease.
• Bigaud E, Corrales FJ.
• Mol Cell Proteomics. 2016 Jan 27. pii: mcp.M115.055772. [Epub ahead of print]
• Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency.
• Collantes M, Serrano-Mendioroz I, Benito M, Molinet-Dronda F, Delgado M, Vinaixa M, Sampedro A, Enríquez de Salamanca R, Prieto E, Pozo MA, Peñuelas I, Corrales FJ, Barajas M, Fontanellas A.
• Hum Mol Genet. 2016 Jan 21
• Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways. Garcia-Ruiz C, Mato JM, Vance D, Kaplowitz N, Fernández-Checa JC. J Hepatol. 2015 Jan;62(1):219-33.
• S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease. Martínez-Uña M, Varela-Rey M, Mestre D, Fernández-Ares L, Fresnedo O, Fernandez-Ramos D, Gutiérrez-de Juan V, Martin-Guerrero I, García-Orad A, Luka Z, Wagner C, Lu SC, García-Monzón C, Finnell RH, Aurrekoetxea I, Buqué X, Martínez-Chantar ML, Mato JM, Aspichueta P. J Hepatol. 2015 Mar;62(3):673-81.
• Enhancing metabolomics research through data mining. Martínez-Arranz I, Mayo R, Pérez-Cormenzana M, Mincholé I, Salazar L, Alonso C, Mato JM. J Proteomics. 2015 Sep 8;127(Pt B):275-88.
• Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.Noureddin M, Mato JM, Lu SC. Exp Biol Med (Maywood). 2015 Jun;240(6):809-20.
• Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis. Zubiete-Franco I, García-Rodríguez JL, Martínez-Uña M, Martínez-Lopez N, Woodhoo A, Juan VG, Beraza N, Lage-Medina S, Andrade F, Fernandez ML, Aldámiz-Echevarría L, Fernández-Ramos D, Falcon-Perez JM, Lopitz-Otsoa F, Fernandez-Tussy P, Barbier-Torres L, Luka Z, Wagner C, García-Monzón C, Lu SC, Aspichueta P, Mato JM, Martínez-Chantar ML, Varela-Rey M. J Hepatol. 2016 Feb;64(2):409-18. Doi
• Crystallography captures catalytic steps in human methionine adenosyltransferase enzymes. Murray B, Antonyuk SV, Marina A, Lu SC, Mato JM, Hasnain SS, Rojas AL. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2104-9. doi:
• Functional Proteomics Study Reveals SUMOylation of TFII-I is Involved in Liver Cancer Cell Proliferation.
• Tu J, Chen Y, Cai L, Xu C, Zhang Y, Chen Y, Zhang C, Zhao J, Cheng J, Xie H, Zhong F, He F.
• J Proteome Res. 2015 Jun 5;14(6):2385-97. doi: 10.1021/acs.jproteome.5b00062. Epub 2015 Apr 29.
• Transcriptome and proteome of human hepatocellular carcinoma reveal shared metastatic pathways with significant genes.
• Shen H, Zhong F, Zhang Y, Yu H, Liu Y, Qin L, He F, Tang Z, Yang P.
• Proteomics. 2015 Jun;15(11):1793-800. doi: 10.1002/pmic.201400275. Epub 2015 Mar 18.
• Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and liver fibrosis by epigenetically regulating peroxisome proliferator-activated receptor γ.
• Jiang Y, Wang S, Zhao Y, Lin C, Zhong F, Jin L, He F, Wang H.
• FASEB J. 2015 May;29(5):1830-41. doi: 10.1096/fj.14-251751. Epub 2015 Jan 21.
• Interactome map reveals phospholipid scramblase 1 as a novel regulator of hepatitis B virus x protein.
  Yuan Y, Tian C, Gong Q, Shang L, Zhang Y, Jin C, He F, Wang J.
  J Proteome Res. 2015 Jan 2;14(1):154-63. doi: 10.1021/pr500943x. Epub 2014 Nov 14.